Lisdexamfetamine Dimesylate Patent Expiration

Lisdexamfetamine Dimesylate is Used for managing symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in both adults and children. It was first introduced by Takeda Pharmaceuticals Usa Inc in its drug Vyvanse on Feb 23, 2007. 16 different companies have introduced drugs containing Lisdexamfetamine Dimesylate.


Lisdexamfetamine Dimesylate Patents

Given below is the list of patents protecting Lisdexamfetamine Dimesylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vyvanse US7105486 Abuse-resistant amphetamine compounds Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7105486 Abuse-resistant amphetamine compounds Jun 29, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7105486

(Pediatric)

Abuse-resistant amphetamine compounds Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7223735 Abuse resistant lysine amphetamine compounds Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7223735 Abuse resistant lysine amphetamine compounds Jun 29, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7223735

(Pediatric)

Abuse resistant lysine amphetamine compounds Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7655630 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7655630 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7655630

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7659253 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7659253 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7659253

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7659254 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7659254

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7662787 Abuse resistant lysine amphetamine compounds Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7662787 Abuse resistant lysine amphetamine compounds Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7662787

(Pediatric)

Abuse resistant lysine amphetamine compounds Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7662788 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7662788

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7671030 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7671030

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7671031 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7671031 Abuse-resistant amphetamine prodrugs Feb 28, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7671031

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7674774 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7674774 Abuse-resistant amphetamine prodrugs Mar 18, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7674774

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7678770 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7678770 Abuse-resistant amphetamine prodrugs Mar 25, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7678770

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7678771 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7678771 Abuse-resistant amphetamine prodrugs Mar 25, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7678771

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7687466 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7687466

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7687467 Abuse-resistant amphetamine prodrugs Apr 08, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7687467 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7687467

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7700561 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7700561 Abuse-resistant amphetamine prodrugs Jun 29, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7700561

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7713936 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7713936

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7718619 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7718619

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7723305 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7723305

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Lisdexamfetamine Dimesylate Generics

Several generic applications have been filed for Lisdexamfetamine Dimesylate. The first generic version for Lisdexamfetamine Dimesylate was by Hikma Pharmaceuticals Usa Inc and was approved on Aug 25, 2023. And the latest generic version is by Msn Laboratories Private Ltd and was approved on Feb 2, 2024.

Given below is the list of companies who have filed for Lisdexamfetamine Dimesylate generic.


1. ASCENT PHARMS INC

Ascent Pharmaceuticals Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Ascent Pharms Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG tablet, chewable Prescription ORAL AB Aug 25, 2023
20MG tablet, chewable Prescription ORAL AB Aug 25, 2023
30MG tablet, chewable Prescription ORAL AB Aug 25, 2023
40MG tablet, chewable Prescription ORAL AB Aug 25, 2023
50MG tablet, chewable Prescription ORAL AB Aug 25, 2023
60MG tablet, chewable Prescription ORAL AB Aug 25, 2023
70MG capsule Prescription ORAL AB Aug 25, 2023


2. HIKMA

Hikma Pharmaceuticals Usa Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Hikma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
70MG capsule Prescription ORAL AB Aug 25, 2023
20MG capsule Prescription ORAL AB Aug 25, 2023
30MG capsule Prescription ORAL AB Aug 25, 2023
40MG capsule Prescription ORAL AB Aug 25, 2023
50MG capsule Prescription ORAL AB Aug 25, 2023
60MG capsule Prescription ORAL AB Aug 25, 2023
10MG capsule Prescription ORAL AB Jan 17, 2024


3. PRINSTON INC

Prinston Pharmaceutical Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Prinston Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG capsule Prescription ORAL AB Aug 25, 2023
20MG capsule Prescription ORAL AB Aug 25, 2023
30MG capsule Prescription ORAL AB Aug 25, 2023
40MG capsule Prescription ORAL AB Aug 25, 2023
50MG capsule Prescription ORAL AB Aug 25, 2023
60MG capsule Prescription ORAL AB Aug 25, 2023
70MG capsule Prescription ORAL AB Aug 25, 2023


4. ACTAVIS ELIZABETH

Actavis Elizabeth Llc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Actavis Elizabeth.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG capsule Discontinued ORAL N/A Aug 25, 2023
20MG capsule Discontinued ORAL N/A Aug 25, 2023
30MG capsule Discontinued ORAL N/A Aug 25, 2023
40MG capsule Discontinued ORAL N/A Aug 25, 2023
50MG capsule Discontinued ORAL N/A Aug 25, 2023
60MG capsule Discontinued ORAL N/A Aug 25, 2023
70MG capsule Discontinued ORAL N/A Aug 25, 2023


5. SPECGX LLC

Specgx Llc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Specgx Llc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG capsule Prescription ORAL AB Aug 25, 2023
20MG capsule Prescription ORAL AB Aug 25, 2023
30MG capsule Prescription ORAL AB Aug 25, 2023
40MG capsule Prescription ORAL AB Aug 25, 2023
50MG capsule Prescription ORAL AB Aug 25, 2023
60MG capsule Prescription ORAL AB Aug 25, 2023
70MG capsule Prescription ORAL AB Aug 25, 2023


6. APOTEX

Apotex Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG capsule Prescription ORAL AB Aug 25, 2023
20MG capsule Prescription ORAL AB Aug 25, 2023
30MG capsule Prescription ORAL AB Aug 25, 2023
40MG capsule Prescription ORAL AB Aug 25, 2023
50MG capsule Prescription ORAL AB Aug 25, 2023
60MG capsule Prescription ORAL AB Aug 25, 2023
70MG capsule Prescription ORAL AB Aug 25, 2023


7. MYLAN

Mylan Pharmaceuticals Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Mylan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG capsule Prescription ORAL AB Aug 25, 2023
20MG capsule Prescription ORAL AB Aug 25, 2023
30MG capsule Prescription ORAL AB Aug 25, 2023
40MG capsule Prescription ORAL AB Aug 25, 2023
50MG capsule Prescription ORAL AB Aug 25, 2023
60MG capsule Prescription ORAL AB Aug 25, 2023
70MG capsule Prescription ORAL AB Aug 25, 2023


8. AMNEAL

Amneal Pharmaceuticals Llc has filed for 6 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Amneal.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20MG capsule Prescription ORAL AB Aug 25, 2023
30MG capsule Prescription ORAL AB Aug 25, 2023
40MG capsule Prescription ORAL AB Aug 25, 2023
50MG capsule Prescription ORAL AB Aug 25, 2023
60MG capsule Prescription ORAL AB Aug 25, 2023
70MG capsule Prescription ORAL AB Aug 25, 2023


9. LANNETT CO INC

Lannett Co Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Lannett Co Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG capsule Prescription ORAL AB Aug 25, 2023
20MG capsule Prescription ORAL AB Aug 25, 2023
30MG capsule Prescription ORAL AB Aug 25, 2023
40MG capsule Prescription ORAL AB Aug 25, 2023
50MG capsule Prescription ORAL AB Aug 25, 2023
60MG capsule Prescription ORAL AB Aug 25, 2023
70MG capsule Prescription ORAL AB Aug 25, 2023


10. SUN PHARM INDS INC

Sun Pharmaceutical Industries Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG capsule Prescription ORAL AB Aug 25, 2023
20MG capsule Prescription ORAL AB Aug 25, 2023
30MG capsule Prescription ORAL AB Aug 25, 2023
40MG capsule Prescription ORAL AB Aug 25, 2023
50MG capsule Prescription ORAL AB Aug 25, 2023
60MG capsule Prescription ORAL AB Aug 25, 2023
70MG capsule Prescription ORAL AB Aug 25, 2023


11. RHODES PHARMS

Rhodes Pharmaceuticals Lp has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Rhodes Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG capsule Prescription ORAL AB Aug 25, 2023
20MG capsule Prescription ORAL AB Aug 25, 2023
30MG capsule Prescription ORAL AB Aug 25, 2023
40MG capsule Prescription ORAL AB Aug 25, 2023
50MG capsule Prescription ORAL AB Aug 25, 2023
60MG capsule Prescription ORAL AB Aug 25, 2023
70MG capsule Prescription ORAL AB Aug 25, 2023


12. ALKEM LABS LTD

Alkem Laboratories Ltd has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG capsule Prescription ORAL AB Aug 25, 2023
20MG capsule Prescription ORAL AB Aug 25, 2023
30MG capsule Prescription ORAL AB Aug 25, 2023
40MG capsule Prescription ORAL AB Aug 25, 2023
50MG capsule Prescription ORAL AB Aug 25, 2023
60MG capsule Prescription ORAL AB Aug 25, 2023
70MG capsule Prescription ORAL AB Aug 25, 2023


13. TEVA PHARMS

Teva Pharmaceuticals Development Inc has filed for 6 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Teva Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG tablet, chewable Discontinued ORAL N/A Aug 25, 2023
20MG tablet, chewable Discontinued ORAL N/A Aug 25, 2023
30MG tablet, chewable Discontinued ORAL N/A Aug 25, 2023
40MG tablet, chewable Discontinued ORAL N/A Aug 25, 2023
50MG tablet, chewable Discontinued ORAL N/A Aug 25, 2023
60MG tablet, chewable Discontinued ORAL N/A Aug 25, 2023


14. NORWICH

Norwich Pharmaceuticals Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Norwich.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG capsule Prescription ORAL AB Aug 25, 2023
20MG capsule Prescription ORAL AB Aug 25, 2023
30MG capsule Prescription ORAL AB Aug 25, 2023
40MG capsule Prescription ORAL AB Aug 25, 2023
50MG capsule Prescription ORAL AB Aug 25, 2023
60MG capsule Prescription ORAL AB Aug 25, 2023
70MG capsule Prescription ORAL AB Aug 25, 2023


15. MSN

Msn Laboratories Private Ltd has filed for 6 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Msn.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG tablet, chewable Prescription ORAL AB Feb 2, 2024
20MG tablet, chewable Prescription ORAL AB Feb 2, 2024
30MG tablet, chewable Prescription ORAL AB Feb 2, 2024
40MG tablet, chewable Prescription ORAL AB Feb 2, 2024
50MG tablet, chewable Prescription ORAL AB Feb 2, 2024
60MG tablet, chewable Prescription ORAL AB Feb 2, 2024